Ovarian Cancer Clinical Trials

Showing 621-640 of 902 trials

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

NCT00102622

The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will also be studied. Researchers will also ask the patients if they will allow additional tumor samples to be collected and extra blood samples to be drawn. These samples will be used to learn about the biological response before and after treatment.

Ovarian Cancer

M.D. Anderson Cancer Center18 participantsStarted Dec 2004

Houston, Texas, United States

COMPLETEDPhase 2

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

NCT01358071

The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone

Ovarian Cancer

AGC Biologics S.p.A.119 participantsStarted Jun 2011

Milan, Italy • Milan, Italy • Milan, Italy +5 more locations

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Related Searches

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study

Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

M. D. Anderson Symptom Inventory - Ovarian Cancer

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer